Case report: combination of immune-related thrombocytopenia and myocarditis in а patient treated with immune checkpoint inhibitors for non‑small cell lung cancer
Journal: Malignant tumours
Year: 2023

Immune-related adverse events (irAE) present a unique challenge in modern oncology. In patient treated with immune checkpoint inhibitors (anti-PD-1, anti-CTLA-4, anti-PD-L1) for solid tumors irAEs rate ranges from 60 to 85 % [1]. irAEs lead to complete treatment discontinuation in approximately 40 % of patients [2]. The most common irAEs are endocrinopathies (up to 10 %), pneumonitis (5 to 10 %), autoimmune hepatitis (up to 20 %), colitis (up to 30 %), and skin toxicity (up to 50 %) [3]. Other f